Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combining resistance and pharmacology for optimum patient care

Combining resistance and pharmacology for optimum patient care SPECIAL COMMENTARY a b a Saye H. Khoo , Alan Winston and David J. Back Purpose of review Abbreviations Therapeutic drug monitoring is now incorporated into the APV amprenavir ATV atazanavir treatment guidelines of many countries. In this review, we CNS central nervous system describe the use and limitations of therapeutic drug CV intra-patient variability EFV efavirenz monitoring, and how added benefit might accrue from DRV darunavir integrating therapeutic drug monitoring with resistance IDV indinavir LPV lopinavir testing in the form of inhibitory quotients. NFV nelfinavir Recent findings NNRTI nonnucleoside reverse transcriptase inhibitor RCT randomized controlled trial Although the unselected use of therapeutic drug monitoring RTV ritonavir in current (ritonavir-boosted) protease inhibitor or SQV saquinavir TDM therapeutic drug monitoring nonnucleoside reverse transcriptase inhibitor-containing TPV tipranavir regimens has yet to be established, therapeutic drug monitoring is likely to be useful in selected groups of patients, such as children, pregnant women, patients with 2007 Lippincott Williams & Wilkins 1746-630X malabsorption, or in specific clinical scenarios, such as liver impairment, drug interactions, suspected toxicity, assessing adherence or treatment failure. One problem with therapeutic drug monitoring is that efficacy targets relate Introduction mainly to drug-sensitive virus. Inhibitory quotients may be a One of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Combining resistance and pharmacology for optimum patient care

Current Opinion in HIV and Aids , Volume 2 (3) – May 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/combining-resistance-and-pharmacology-for-optimum-patient-care-DN0DlBRw6Q

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3280f31d27
pmid
19372882
Publisher site
See Article on Publisher Site

Abstract

SPECIAL COMMENTARY a b a Saye H. Khoo , Alan Winston and David J. Back Purpose of review Abbreviations Therapeutic drug monitoring is now incorporated into the APV amprenavir ATV atazanavir treatment guidelines of many countries. In this review, we CNS central nervous system describe the use and limitations of therapeutic drug CV intra-patient variability EFV efavirenz monitoring, and how added benefit might accrue from DRV darunavir integrating therapeutic drug monitoring with resistance IDV indinavir LPV lopinavir testing in the form of inhibitory quotients. NFV nelfinavir Recent findings NNRTI nonnucleoside reverse transcriptase inhibitor RCT randomized controlled trial Although the unselected use of therapeutic drug monitoring RTV ritonavir in current (ritonavir-boosted) protease inhibitor or SQV saquinavir TDM therapeutic drug monitoring nonnucleoside reverse transcriptase inhibitor-containing TPV tipranavir regimens has yet to be established, therapeutic drug monitoring is likely to be useful in selected groups of patients, such as children, pregnant women, patients with 2007 Lippincott Williams & Wilkins 1746-630X malabsorption, or in specific clinical scenarios, such as liver impairment, drug interactions, suspected toxicity, assessing adherence or treatment failure. One problem with therapeutic drug monitoring is that efficacy targets relate Introduction mainly to drug-sensitive virus. Inhibitory quotients may be a One of

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: May 1, 2007

There are no references for this article.